pd-l1 antibody
PD-L1 Antibody |
|||
49251-100ul | SAB | 100ul | 399.6 EUR |
PD-L1 Antibody |
|||
49251-50ul | SAB | 50ul | 286.8 EUR |
PD-L1 Antibody |
|||
P1013-01m | SAB | 0.1m | 224.4 EUR |
PD-L1 Antibody |
|||
P1013-1ml | SAB | 1ml | 807.6 EUR |
PD-L1 Antibody |
|||
R31573 | NSJ Bioreagents | 100 ug | 356.15 EUR |
Description: Programmed death-ligand 1, also known as CD274 or B7-H1 is a protein that in humans is encoded by the CD274 gene. It is a 33-70kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. Upregulation on tumor MDCs downregulates T-cell immunity and PD-L1 blockade may represent an approach for cancer immunotherapy. It can provide positive costimulatory signals for innate and adaptive immunity and for protection against intracellular bacterial infection. It has been found that PD1/PDL1 pathway may be a good target for restoring antitumor immunity in ovarian cancer. |
|||
PD-L1 Antibody |
|||
R33263-100UG | NSJ Bioreagents | 100 ug | 339.15 EUR |
Description: Additional name(s) for this target protein: Programmed cell death 1 ligand 1; CD274 |
|||
PD-L1 Antibody |
|||
DF6526 | Affinity Biosciences | 100ul | 280 EUR |
Description: Human,Mouse,Rat |
|||
PD-L1 Antibody |
|||
DF6526-100ul | Affinity Biosciences | 100ul | 280 EUR |
PD-L1 Antibody |
|||
DF6526-200ul | Affinity Biosciences | 200ul | 350 EUR |
Anti-PD-L1 Antibody |
|||
A1454-100 | Biovision | each | 405.6 EUR |
Anti-PD-L1 Antibody |
|||
A1454-30T | Biovision | each | 175.2 EUR |
Anti-PD-L1 antibody |
|||
STJ180217 | St John's Laboratory | 0.1 ml | 336 EUR |
Anti-PD-L1 antibody |
|||
STJ180383 | St John's Laboratory | 0.1 ml | 295.2 EUR |
Anti-PD-L1 antibody |
|||
STJ190082 | St John's Laboratory | 200 µl | 236.4 EUR |
Description: Unconjugated Mouse monoclonal to PD-L1 (AS1A7) |
|||
Anti-PD-L1 antibody |
|||
STJ130022 | St John's Laboratory | 50 µl | 385.2 EUR |
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies. |
|||
Anti-PD-L1 antibody |
|||
STJ130023 | St John's Laboratory | 50 µl | 385.2 EUR |
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies. |
|||
Anti-PD-L1 antibody |
|||
STJ130024 | St John's Laboratory | 50 µl | 385.2 EUR |
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies. |
|||
PD-L1 Antibody [F6A9] |
|||
SD8639-002mg | ProSci | 0.02 mg | 253.22 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. |
|||
PD-L1 Antibody [F6A9] |
|||
SD8639-01mg | ProSci | 0.1 mg | 723.62 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. |
|||
PD-L1 Antibody [F2G2] |
|||
SD8641-002mg | ProSci | 0.02 mg | 253.22 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. |
|||
PD-L1 Antibody [F2G2] |
|||
SD8641-01mg | ProSci | 0.1 mg | 723.62 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. |
|||
Mouse PD-L1 Antibody |
|||
32903-05111 | AssayPro | 150 ug | 313.2 EUR |
PD-L1/CD274 antibody |
|||
CAF50592-100ug | Biomatik Corporation | 100ug | 312 EUR |
PD-L1 Conjugated Antibody |
|||
C49251 | SAB | 100ul | 476.4 EUR |
PD-L1 Monoclonal Antibody |
|||
CAC10271-100ul | Biomatik Corporation | 100ul | 367.5 EUR |
PD-L1 Monoclonal Antibody |
|||
CAC10271-50ul | Biomatik Corporation | 50ul | 252 EUR |
PD-L1 Polyclonal Antibody |
|||
E911273a | EnoGene | 100ul | 225 EUR |
Description: Available in various conjugation types. |
|||
anti- PD-L1/CD274 antibody |
|||
FNab06280 | FN Test | 100µg | 606.3 EUR |
Description: Antibody raised against PD-L1/CD274 |
|||
anti- PD-L1/CD274 antibody |
|||
FNab06281 | FN Test | 100µg | 658.5 EUR |
Description: Antibody raised against PD-L1/CD274 |
|||
anti-PD-L1 VHH antibody |
|||
JOT0002-5 | Jotbody | each | Ask for price |
anti-PD-L1 VHH antibody |
|||
JOT0002-5-1-100 | Jotbody | 100 | 148.12 EUR |
Description: Primary VHH single domain antibody |
|||
anti-PD-L1 VHH antibody |
|||
JOT0002-5-1-1000 | Jotbody | 1000 | 880.6 EUR |
Description: Primary VHH single domain antibody |
|||
anti-PD-L1 VHH antibody |
|||
JOT0002-5-1-2000 | Jotbody | 2000 | 1565.2 EUR |
Description: Primary VHH single domain antibody |
|||
anti-PD-L1 VHH antibody |
|||
JOT0002-5-1-250 | Jotbody | 250 | 246.17 EUR |
Description: Primary VHH single domain antibody |
|||
anti-PD-L1 VHH antibody |
|||
JOT0002-5-1-50 | Jotbody | 50 | 89.54 EUR |
Description: Primary VHH single domain antibody |
|||
PD-L1 Antibody (IHC Gold) |
|||
E36PA411 | EnoGene | 100ul | 225 EUR |
Description: Available in various conjugation types. |
|||
Anti-PD-L1/CD274 Antibody |
|||
PB9994 | BosterBio | 100ug/vial | 352.8 EUR |
Anti-PD-L1/CD274 Antibody |
|||
PB9154 | BosterBio | 100ug/vial | 352.8 EUR |
Anti-PD-L1/CD274 Antibody |
|||
PA1851 | BosterBio | 100ug/vial | 352.8 EUR |
Anti-PD-L1/CD274 antibody |
|||
PAab06280 | Lifescience Market | 100 ug | 426 EUR |
Anti-CD274 / PD-L1 antibody |
|||
STJ70646 | St John's Laboratory | 100 µg | 430.8 EUR |
Anti-PD-L1 Antibody (IHC411) |
|||
A1549-50 | Biovision | each | 222 EUR |
OASL01224-50UL - PD-L1 Antibody |
|||
OASL01224-50UL | Aviva Systems Biology | 50ul | 269 EUR |
Rabbit Polyclonal PD-L1 Antibody |
|||
TA306401 | Origene Technologies GmbH | 100 µg | Ask for price |
Ribosome-inactivating protein PD-L1 / PD-L2 Antibody |
|||
20-abx319445 | Abbexa |
|
|
Ribosome-inactivating protein PD-L1/PD-L2 Antibody |
|||
1-CSB-PA306294LA01PJJ | Cusabio |
|
|
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Unconjugated. Tested in the following application: ELISA |
|||
Anti-PD-L1 Antibody [PD01-02] |
|||
HA721176 | HUABIO | 100ul | 231 EUR |
Description: PD-L1 (programmed-death ligand 1; CD274), is a transmembrane protein constitutionally expressed on a variety of cell types, including antigen presenting cells (dendritic cells and histiocytes) and some non-lymphoid tissues (heart and lung). Binding of PD-L1 to PD-1 (programmed-death 1; CD279) expressed by activated T-cells, inhibits their function, causing negative feedback control of immunological reactions, thus impeding inflammation and autoimmunity. Tumour cells may express PD-L1, which binds to PD-1 allowing cancer cells to evade the attack of T-cells. Blockade of the PD-1/PD-L1 pathway has now shown useful in therapy of multiple cancer types, causing durable tumour regressions in a substantial proportion of otherwise treatment refractory cases of melanoma, and carcinomas of e.g., lung, kidney, and urinary tract. Patients without tumour PD-L1 expression can also derive benefit from blocking agents (studies across multiple cancer types demonstrate a pooled response rate of 48% in patients with PD-L1-positive tumours compared to 15% in PD-L1-negative tumours). Tonsil and placenta can be used as positive and negative tissue controls. However, tonsil is found to be superior to placenta, as tonsil displayes a range of PD-L1 expression levels. Tonsil displayes the following reaction pattern: No staining reaction in the vast majority of lymphocytes including mantle zone and germinal centre B-cells, no staining reaction in superficial epithelial cells, a weak to moderate, typically punctuated membranous staining reaction of the majority of germinal centre macrophages and finally a moderate to strong staining reaction of the majority of epithelial crypt cells. |
|||
Anti-PD-L1 Antibody [JJ08-95] |
|||
ET1701-41 | HUABIO | 100ul | 231 EUR |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T cell proliferation, cytokine production, differentiation of effector T cells, and the induction of Bcl-x, a promoter of T cell survival. Conversely, engagement of CTLA4 by B7-1 or B7-2 may inhibit proliferation and IL-2 production. Pdcd-1L1 (programmed cell death ligand-1), also known as B7-H1 or PD-L1, is 290 amino acid type I transmembrane protein which is 20% and 15% identical to B7-1 and B7-2, respectively. Pdcd-1L2 has immunoglobulin V-like and C-like domains and a 30 amino acid cytoplasmic tail. It does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of Pdcd-1L1 co-stimulation. The gene which encodes Pdcd-1L1 maps to human chromosome 9p24. Pdcd-1L2 (programmed cell death ligand-2) is a 73 amino acid protein which contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The gene which encodes Pdcd-1L2 maps to human chromosome 9p24.2. The constitutive expression of Pdcd-1L1 and Pdcd-1L2 on paren-chymal cells of heart, lung and kidney suggests that the Pdcd-1-Pdcd-L system could provide unique negative signaling to help prevent autoimmune disease. |
|||
Anti-PD-L1 Antibody [JJ08-95] |
|||
ET1701-41TR | HUABIO | 20ul | 64.35 EUR |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T cell proliferation, cytokine production, differentiation of effector T cells, and the induction of Bcl-x, a promoter of T cell survival. Conversely, engagement of CTLA4 by B7-1 or B7-2 may inhibit proliferation and IL-2 production. Pdcd-1L1 (programmed cell death ligand-1), also known as B7-H1 or PD-L1, is 290 amino acid type I transmembrane protein which is 20% and 15% identical to B7-1 and B7-2, respectively. Pdcd-1L2 has immunoglobulin V-like and C-like domains and a 30 amino acid cytoplasmic tail. It does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of Pdcd-1L1 co-stimulation. The gene which encodes Pdcd-1L1 maps to human chromosome 9p24. Pdcd-1L2 (programmed cell death ligand-2) is a 73 amino acid protein which contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The gene which encodes Pdcd-1L2 maps to human chromosome 9p24.2. The constitutive expression of Pdcd-1L1 and Pdcd-1L2 on paren-chymal cells of heart, lung and kidney suggests that the Pdcd-1-Pdcd-L system could provide unique negative signaling to help prevent autoimmune disease. |
|||
PD-L1 Antibody / B7-H1 / CD274 |
|||
F55054-0.1ML | NSJ Bioreagents | 0.1ml | 339.15 EUR |
Description: As a ligand for the inhibitory receptor PDCD1/PD-1, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response. [UniProt] |
|||
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7822-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
|||
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7822-20UG | NSJ Bioreagents | 20 ug | 153.3 EUR |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
|||
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7822SAF-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
|||
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7823-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
|||
PD-L1 Antibody / B7-H1 / CD274 |
|||
V7823-20UG | NSJ Bioreagents | 20 ug | 153.3 EUR |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |